Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves chronic plaque psoriasisPhase 3 topline data anticipated first half of 2021.
Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema
01:00pm, Monday, 13'th Jul 2020
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitorsCompany expects topline data in the second.
MyoKardia's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
04:07am, Thursday, 25'th Jun 2020
MyoKardia's danicamtiv trial yields positive results. Ziopharm completes enrolment for trial of Ad-RTS-hIL-12 with veledimex in combination with Regeneron' Libt
Is Arcutis Biotherapeutics, Inc. (ARQT) Going to Burn These Hedge Funds?
03:47pm, Monday, 22'nd Jun 2020
In this article you are going to find out whether hedge funds think Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a good investment right now. We like to check what the smart money thinks first befor
Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulationSeborrheic dermatitis affects over 6 million U.S. patientsPhase 2 topline data anticipated.
Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference
08:05pm, Wednesday, 10'th Jun 2020
WESTLAKE VILLAGE, Calif., June 10, 2020 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing.
Ayisha Jeter Joins Arcutis as Vice President of Market Access
01:00pm, Monday, 01'st Jun 2020
WESTLAKE VILLAGE, Calif., June 01, 2020 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing.
Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations
01:00pm, Wednesday, 27'th May 2020
In this new role, Mr. Ramsinghani will be responsible for Arcutis’ commercial operations efforts as the Company prepares for the potential future commercialization of its product candidates. “Jay
Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update
08:05pm, Tuesday, 12'th May 2020
Multiple important Phase 3 and Phase 2 data events anticipated during 2020/2021Arcutis currently expects no impact to its previously disclosed clinical timelines due to.
Halley E. Gilbert Appointed to Arcutis Board of Directors
12:30pm, Monday, 27'th Apr 2020
WESTLAKE VILLAGE, Calif., April 27, 2020 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing.
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema
01:00pm, Tuesday, 21'st Apr 2020
“Hand eczema is one of the most common skin diseases, affecting approximately 8 million Americans, and currently there are no FDA-approved therapies for this affliction,” said Howard Welgus, M.D.,
Frazier Healthcare Partners Adds Experienced Pharmaceutical Executive As Venture Partner on Life Sciences Team
12:00pm, Tuesday, 21'st Apr 2020
Frazier Healthcare Partners announced Robert Hershberg, M.D., Ph.D. has rejoined the Life Sciences team as a Venture Partner. He has over 25 years of
I-Mab (NASDAQ:ARQT) Given Average Recommendation of "Strong Buy" by Brokerages
10:08am, Saturday, 11'th Apr 2020
I-Mab (NASDAQ:ARQT) has been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investmen
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Be
Kimberly Lathroum Joins Arcutis as Vice President of Marketing
12:30pm, Monday, 23'rd Mar 2020
WESTLAKE VILLAGE, Calif., March 23, 2020 -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing.
